A detailed history of Bellevue Group Ag transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 15,700 shares of DNLI stock, worth $326,246. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,700
Holding current value
$326,246
% of portfolio
0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$20.96 - $31.05 $329,072 - $487,485
15,700 New
15,700 $457,000
Q2 2023

Aug 14, 2023

BUY
$23.37 - $32.96 $304,978 - $430,128
13,050 Added 42.1%
44,050 $1.3 Million
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $805,070 - $1.19 Million
31,000 New
31,000 $951,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.79B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.